Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences marks milestone quarter with key clinical wins, Beckley merger plans
08:51am, Thursday, 14'th Aug 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from i
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
05:01pm, Monday, 28'th Jul 2025
Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed st
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
10:58am, Monday, 28'th Jul 2025
Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
08:29am, Monday, 28'th Jul 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment ass
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:13am, Monday, 28'th Jul 2025
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial
04:16pm, Friday, 25'th Jul 2025
Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schiz
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its ran
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate
04:38pm, Wednesday, 23'rd Jul 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and e
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003
01:08pm, Wednesday, 23'rd Jul 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and e
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
01:01pm, Monday, 21'st Jul 2025
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
11:42am, Friday, 18'th Jul 2025
Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies an
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 11'th Jul 2025
Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
atai Life Sciences price target boosted on robust BPL-003 mid-stage trial results
03:59pm, Wednesday, 02'nd Jul 2025
The atai Life Sciences (NASDAQ:ATAI, ETR:9VC) story has become more attractive following the release of robust Phase 2b trial results for BPL-003 in treatment-resistant depression, analysts at Jefferi
Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD
02:29pm, Wednesday, 02'nd Jul 2025
Atai Life Sciences' BPL-003 showed robust, rapid, and durable antidepressant effects in Phase 2b TRD data, spiking shares over 20%. BPL-003's short clinic time and strong efficacy could fit existing t
Atai and Beckley Psytech hail DMT trial results in treatment-resistant depression
07:08am, Wednesday, 02'nd Jul 2025
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced positive topline results from its Phase 2b clinical study in patients with treatment-resistant depression, and a private placement for gross proce
